Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CTNNB1 |
Variant | G34R |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | CTNNB1 G34R lies within the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 15064718). G34R is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 in culture (PMID: 10597262, PMID: 10671680). |
Associated Drug Resistance | |
Category Variants Paths |
CTNNB1 mutant CTNNB1 act mut CTNNB1 G34R |
Transcript | NM_001098210.2 |
gDNA | chr3:g.41224612G>A |
cDNA | c.100G>A |
Protein | p.G34R |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047447479.1 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
NM_001098209.2 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_024453358.1 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
NM_001098209.1 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_006712985.1 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_047447480.1 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
NM_001904.3 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_024453356.2 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_024453356.1 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_024453357.1 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_047447477.1 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
NM_001904.4 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_047447481.1 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_017005738 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_005264886 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_017005738.2 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
NM_001098210.2 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_047447478.1 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_017005738.1 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
NM_001098210 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_006712985 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
NM_001904 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
NM_001098209 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
NM_001098210.1 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_006712985.2 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
XM_047447483.1 | chr3:g.41224612G>A | c.100G>A | p.G34R | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CTNNB1 G34R | hepatocellular carcinoma | predicted - sensitive | Everolimus + Sorafenib | Case Reports/Case Series | Actionable | In a clinical case study, Afinitor (everolimus) and Nexavar (sorafenib) combination therapy resulted in a 50% tumor response after 3 months of treatment in a patient with metastatic hepatocellular carcinoma harboring CTNNB1 G34R whose disease progressed on prior Nexavar (sorafenib) monotherapy, and the response was ongoing at 8 months (PMID: 20347502). | 20347502 |